Related Experiment Video
Updated: Dec 17, 2025

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Host range, morphological and genomic characterisation of bacteriophages with activity against clinical Streptococcus
Lucy L Furfaro1, Matthew S Payne1, Barbara J Chang2
1The School of Medicine, Division of Obstetrics and Gynaecology, The University of Western Australia, Crawley, Australia.
Insights
Bacteriophages (phages) show promise for treating Group B Streptococcus (GBS) infections in newborns. Four novel phages demonstrated significant lytic activity against GBS clinical isolates, offering a potential alternative to antibiotics.
Area of Science:
- Microbiology
- Virology
- Genetics
Background:
- Group B Streptococcus (GBS) is a primary cause of neonatal sepsis.
- Antibiotic prophylaxis for GBS colonization in pregnant women carries risks like resistance and microbiome disruption.
- Bacteriophages (phages) offer a targeted therapeutic alternative.
Purpose of the Study:
- To isolate and characterize bacteriophages with lytic activity against Streptococcus agalactiae.
- To evaluate the potential of these phages for therapeutic applications against GBS.
Main Methods:
- Isolation of four bacteriophages (LF1-LF4) from wastewater.
- In vitro testing of phage lytic activity against clinical S. agalactiae isolates.
- Genomic analysis of isolated phages.
Main Results:
- 77.2% of maternal and 100% of neonatal S. agalactiae isolates were susceptible to at least one phage.
- Phage genomes ranged from 32,205-44,768 bp, belonging to the Siphoviridae family.
- Phages exhibited varying degrees of relatedness to known S. agalactiae and S. pyogenes prophages, with evidence of temperate characteristics.
Conclusions:
- Isolated phages display broad host range activity against clinical GBS isolates.
- Despite being temperate, these phages show potential for therapeutic development, including bioengineered phage or lysin applications.
Abstract:
Streptococcus agalactiae or Group B Streptococcus (GBS) is a leading cause of sepsis in neonates. As a preventative measure prophylactic antibiotic administration is common in pregnant women colonised with GBS, but antibiotic-resistance and adverse effects on neonatal microbiomes may result. Use of bacteriophages (phages) is one option for targeted therapy. To this end, four phages (LF1 -LF4) were isolated from wastewater. They displayed lytic activity in vitro against S. agalactiae isolates collected from pregnant women and neonates, with 190/246 isolates (77.2%) and 10/10 (100%) isolates susceptible to at least one phage, respectively. Phage genomes ranged from 32,205-44,768 bp and all phages were members of the Siphoviridae family. High nucleotide identity (99.9%) was observed between LF1 and LF4, which were closely related to a putative prophage of S. agalactiae. The genome organisation of LF2 differed, and it showed similarity to a different S. agalactiae prophage, while LF3 was more closely related to a Streptococcus pyogenes phage. Lysogenic gene presence (integrase, repressor and regulatory modules), was suggestive of temperate phages. In a therapeutic context, temperate phages are not ideal candidates, however, the broad host range activity of these phages observed on clinical isolates in vitro is promising for future therapeutic approaches including bioengineered phage or lysin applications.
More Related Videos
Related Concept Videos
DNA Bacteriophages
Lytic Cycle of Bacteriophages
Modern Molecular Taxonomy
Bacterial Phylum Bacteroidota
Methods of Classification and Identification
Lysogenic Cycle of Bacteriophages

